Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2014 | 12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights

John Gribben, Myron Czuczman, Randy Gascoyne and Wyndham Wilson • 5 Sep 2014
iwNHL 2014
General Non-Hodgkin Lymphoma

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada), Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day one of the 12th iwNHL.

More from John Gribben

Investigating the treatment preferences of physicians in R/R follicular lymphoma
2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
The future of CLL therapy
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Myron Czuczman

Update of targeted or chemotherapy-free therapies in lymphoma
10:51
Update of targeted or chemotherapy-free therapies in lymphoma
John Gribben et al. • 5 Sep 2014
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015

More from Randy Gascoyne

Lymphoma Microenvironment: biology and therapy (part 2/3)
2:20
Lymphoma Microenvironment: biology and therapy (part 2/3)
John Gribben et al. • 5 Sep 2014
Lymphoma microenvironment: biology and therapy (part 1/3)
5:59
Lymphoma microenvironment: biology and therapy (part 1/3)
John Gribben et al. • 5 Sep 2014
Lymphoma microenvironment: biology and therapy (part 3/3)
7:27
Lymphoma microenvironment: biology and therapy (part 3/3)
John Gribben et al. • 5 Sep 2014
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
9:18
iwNHL 2015 roundtable: Using B-cell biology to inform therapy
Kieron Dunleavy et al. • 3 Oct 2015

More from Wyndham Wilson

Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
4:17
Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
Wyndham Wilson • 2 Jul 2019
Liquid biopsy to measure MRD
1:12
Liquid biopsy to measure MRD
Wyndham Wilson • 2 Jul 2019
ViPOR regimen for R/R B-cell lymphoma
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson • 2 Jul 2019
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
2:49
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
Wyndham Wilson • 2 Jul 2019

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI in clinical decision-making
2:25
Addressing the risk of over-reliance on AI in clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
The content of VJHemOnc is intended for healthcare professionals